Michl, M.
Taverna, F.
Kumbrink, J.
Schiergens, T. S.
Heinemann, V.
Engel, J.
Kirchner, T.
Neumann, Jens http://orcid.org/0000-0001-9200-441X
Funding for this research was provided by:
Association for the Promotion of Science and Research at the Medical Faculty of the Ludwig-Maximilians-University Munich
Article History
Received: 18 September 2020
Revised: 25 November 2020
Accepted: 1 December 2020
First Online: 9 December 2020
Compliance with ethical standards
:
: Marlies Michl received honoraria for talks by SIRTeX, Roche and MSD and travel expenses by SIRTeX, Amgen and Merck. Joerg Kumbrink received honoraria and reimbursement for travel and accommodation from AstraZeneca, Novartis, Quality Initiative in Pathology (QuIP) and Roche. Francesco Taverna and Jutta Engel declare no conflict of interest. Volker Heinemann received honoraria for talks, advisory boards and travel expenses by Merck, Amgen, Roche, Takeda, Servier, Pierre Fabre, Taiho, Lilly Oncology, Servier, Sanofi and Bayer Pharmaceuticals. Thomas Kirchner received honoraria for Consulting/Advisory by Amgen, AstraZeneca, Merck KGaA, MSD, Novartis, Pfizer and Roche, for Research Funding by Merck and Roche; for talks by Merck, Astra Zeneca. Jens Neumann received honoraria for talks by Roche, Pfizer, MSD, Pierre Fabre and Falk.
: The study was approved by the local ethical review committee (approval number 18-105) and conducted according to the Declaration of Helsinki.